J. Rossouw, G. Anderson, and R. Prentice, Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial, JAMA, vol.288, pp.321-354, 2002.

E. Barrett-connor, Fortnightly review: Hormone replacement therapy, BMJ, vol.317, issue.7156, pp.457-61, 1998.
DOI : 10.1136/bmj.317.7156.457

V. Beral, Breast cancer and hormone-replacement therapy: the Million Women Study, The Lancet, vol.362, issue.9392, pp.419-446, 2003.
DOI : 10.1016/S0140-6736(03)14596-5

B. Seradour, H. Allemand, A. Weill, and P. Ricordeau, Changes by age in breast cancer incidence, mammography screening and hormone therapy use in France from, Bull Cancer, vol.96, pp.1-6, 2000.

V. Ringa, X. Fritel, N. Varnoux, M. Zins, C. Quelen et al., Discontinuation of hormone therapy in the French GAZEL cohort, Fertil Steril, 1990.
URL : https://hal.archives-ouvertes.fr/inserm-00412633

M. Goldberg, A. Leclerc, and S. Bonenfant, Cohort profile: the GAZEL Cohort Study, International Journal of Epidemiology, vol.36, issue.1, pp.32-39, 2007.
DOI : 10.1093/ije/dyl247

URL : https://hal.archives-ouvertes.fr/inserm-00150053

A. Fournier, F. Berrino, and F. Clavel-chapelon, Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study, Breast Cancer Research and Treatment, vol.95, issue.1, pp.103-114, 2008.
DOI : 10.1007/s10549-007-9523-x

URL : https://hal.archives-ouvertes.fr/inserm-00201813

V. Ringa, N. Varnoux, S. Piault, and G. Breart, Hormone therapy use among postmenopausal French women before the publication of the Women???s Health Initiative Study: duration of use and factors associated with discontinuation, Fertility and Sterility, vol.83, issue.6, pp.1771-79, 2005.
DOI : 10.1016/j.fertnstert.2004.12.040

H. Allemand, B. Seradour, A. Weill, and P. Ricordeau, Decline in breast cancer incidence in, Bull Cancer, vol.95, pp.11-15, 2005.

I. Lowy and G. Weisz, French hormones: progestins and therapeutic variation in France, Social Science & Medicine, vol.60, issue.11, pp.2609-2631, 2005.
DOI : 10.1016/j.socscimed.2004.10.021

P. Scarabin, E. Oger, and . Plu-bureau, Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk, The Lancet, vol.362, issue.9382, pp.428-460, 2003.
DOI : 10.1016/S0140-6736(03)14066-4

URL : https://hal.archives-ouvertes.fr/hal-01026273

A. Fournier, F. Berrino, E. Riboli, V. Avenel, and F. Clavel-chapelon, Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort, International Journal of Cancer, vol.158, issue.3, pp.448-54, 2005.
DOI : 10.1002/ijc.20710

URL : https://hal.archives-ouvertes.fr/inserm-00129104

A. Hersh, M. Stefanick, and R. Stafford, National Use of Postmenopausal Hormone Therapy, JAMA, vol.291, issue.1, pp.47-53, 2004.
DOI : 10.1001/jama.291.1.47

L. Parente, C. Uyehara, W. Larsen, B. Whitcomb, and J. Farley, Long-term impact of the women???s health initiative on HRT, Archives of Gynecology and Obstetrics, vol.47, issue.3, pp.219-243, 2008.
DOI : 10.1007/s00404-007-0442-1

G. Wegienka, S. Havstad, and J. Kelsey, Menopausal Hormone Therapy in a Health Maintenance Organization before and after Women's Health Initiative Hormone Trials Termination, Journal of Women's Health, vol.15, issue.4, pp.369-78, 2006.
DOI : 10.1089/jwh.2006.15.369